The Importance of an NCI SPORE Grant

Jeffrey S. Weber, MD, PhD
Published Online: October 31, 2013
Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, comments on the importance of a Specialized Programs of Research Excellence (SPORE) grant.

Clinical Pearls

  • A Specialized Programs of Research Excellence (SPORE) grant is given out by the NCI
  • SPORE grants bring together investigators from all different disciplines focused on one histology
  • As a part of the SPORE grant given to Moffitt Cancer Center, each project has preclinical laboratory pieces leading to a clinical trial
  • Two out of three SPORE projects at Moffitt currently have clinical trials ongoing


Related Articles
Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.
The FDA approved nivolumab for patients with advanced melanoma in December 2014, joining 6 other melanoma treatments approved in the past 3 years, including monoclonal antibodies pembrolizumab and ipilimumab.
The FDA has approved nivolumab (Opdivo) for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor, based on data from the phase III CheckMate-037 trial.
The programmed death receptor-1 (PD-1) ligand, PD-L1, has become a viable target for immunotherapy in cancer, with multiple antibodies now in development.
JTT Articles
Management of Hepatocellular Cancer
Mutant-Specific Epidermal Growth Factor Receptor Inhibitors
HPV Test With Genotyping Supplants Pap Test
External Resources

AJMC
Cure
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.